Ganirelix Research

Brader J, Ramphul R

A woman in her 20s developed IgA vasculitis with nephritis (IgAVN), which started four days after oocyte donation (for in-vitro fertilisation (IVF) and transfer to another recipient). Prior to oocyte retrieval, the patient received a course of controlled ovarian stimulation (COS) with menotrophin...

Li J, Gong F, Geng L, Wang X, Wei Z, Liu J et al.

This study aimed to evaluate the safety and effectiveness of ganirelix acetate for Chinese women undergoing ovarian stimulation (OS) in real-world clinical practice.This multicenter (16), prospective, single-arm, observational, post-authorization safety study included 1025 Chinese women receiving...

Peng X, Lv X, Li P, Li Y, Hu Y, Zhang Y et al.

This study aimed to compare the safety, efficacy, and clinical predictors of live birth outcomes between cetrorelix and ganirelix in GnRH antagonist protocols during controlled ovarian stimulation.In this retrospective cohort study conducted at a reproductive medicine center (June 2019-June 2022)...

Yang Y, Cui Z, Feng X, Zou F, Wu X

Ganirelix, a third-generation GnRH antagonist, is widely used in assisted reproductive technology (ART) for rapid pituitary suppression to prevent premature luteinizing hormone (LH) surges. Despite its extensive clinical use, real-world evidence on its safety in large populations remains scarce. ...

Moens V, Fontes Jiménez J, Ferrando Serrano M, Ordóñez Pérez D, Muñoz E, Álvarez Pinochet C et al.

How widely is the freeze-all strategy implemented in clinical practice, and what are its indications?This multicentre, prospective observational study included women aged ≥18 years with subfertility and a clinical indication for IVF or intracytoplasmic sperm injection (ICSI) across 24 Span...

Chester M, Devillers MM, Corre R, Giton F, Souaré F, Petrovic CH et al.

What is the effect of attenuating the physiological hypergonadotropic activity encountered at minipuberty on female reproductive function in a mouse model?Decreasing the surge of gonadotropins at minipuberty extended reproductive lifespan, coinciding with alterations in neuroendocrine and ovarian...

Patel S, Saxena B, Mehta P, Niazi SK

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial therapeutic development, providing fast and reversible sup...

Soliman D, Naoom R, Zaied M, Soliman S

To compare in vitro fertilization treatment outcomes for the oral gonadotropin-releasing hormone (GnRH) antagonist elagolix (E) to the conventionally used injectable GnRH antagonist ganirelix (G) for achieving pituitary gonadotropin suppression during a controlled ovarian stimulation (COS) c...

Gopinath M, Khadijah IS, Ruhaima R, Nuguelis R, Mukhri H

Micronutrients influence female fertility, thus adequate levels are important for oocyte quality, maturation, fertilisation and implantation. This study prospectively evaluated the impact of oral multinutrient supplementation on fertility outcomes in In vitro fertilisation or Intracytoplasmic spe...

Rose MB, Sicard AB, Aguiar NA, Onório BO, Almendra AAR, Matheus WE et al.

Non-obstructive azoospermia (NOA) is the most severe form of male factor infertility. It results form from either primary or secondary testicular failure. Here, we report cases of two patients with NOA due to maturation arrest and increased serum FSH, treated with GnRH agonist and gonadotrophins....

Mule D, Chaturvedi S, Badgujar D, Paritala ST, Sharma N, Shah RP et al.

The concept of extractables and leachable has introduced a new era for identifying potential impurities in drug products. Pharmaceutical packaging materials encompass a variety of polymers due to their appealing properties for storing the drug product. However, numerous chemical species may leach...

Mouanness M, Merhi Z

The injectable gonadotropin-releasing hormone (GnRH) antagonists have traditionally been used for ovulation suppression during controlled ovarian hyperstimulation for in vitro fertilization (IVF), leading to increased painful daily injections and cost. The use of the oral GnRH antagonist elagolix...

Castillo J, Quaas AM, Kol S

Luteinizing hormone (LH) is present throughout the natural follicular phase. However, the debate is still not settled on whether LH is needed during ovarian stimulation in IVF. This commentary looks at the evolution of this debate, mentioning three elephants in the room that were ignored by the P...

Jadav R, Kameriya R, Chatterjee S, Gour V, Purohit P, Bandyopadhyay A et al.

Ganirelix, a peptide-based drug used to treat female infertility, has been in high market demand, which attracted generic formulation. A hitherto unknown impurity of ganirelix was observed in our formulation process, which reached ~0.3% in 6 months and led to a detailed investigation of its ...

Takeuchi K, Orita Y, Iwakawa T, Kuwatsuru Y, Kuroki Y, Fukumoto Y et al.

The delayed-start gonadotropin-releasing hormone antagonist protocol seems effective for patients who are poor ovarian responders, but there are insufficient data on whether it is also effective for patients with poor-quality embryos and low rates of good blastocyst formation. Specifically, the e...

Dragotto J, Buzzaccarini G, Etrusco A, Laganà AS, Venezia R, Terzic S et al.

Luteinizing hormone (LH) plays a key role in normal follicular development and oocyte maturation in controlled ovarian stimulation. LH stimulates the proliferation and differentiation of theca cells for the secretion of androgens, synergistically increasing estrogen production. This study aimed t...

Sönmez Ünal G, Albak Y, Yurtcu N, Yıldız Ç, Çetin M, Durna Daştan S et al.

This study aimed to investigate the efficacy of metformin and ganirelix on subcutaneous endometriotic tissues created in an experimental mouse model.Five groups were formed with eight animals in each group. One of the groups was set as the control group. Endometriotic lesions were created by tran...

Boniface C, Schnorr JN, Gray J, McLaughlin J, Cook H, Slowey M et al.

To study the clinical use of elagolix in ovarian stimulation and its effect on premature ovulation in a cohort of women undergoing oocyte donation.A prospective cohort study with the use of historical controls.A private reproductive endocrinology and infertility clinic.Seventy-five oocyte donors ...

Mannaerts B

Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was the minimal, effective daily dose to prevent premature lut...

Chatterjee S, Bandyopadhyay A

Controlling certain diseases using peptide drugs has remarkably increased in the past two decades. In this regard, a generic formulation is an upfront solution to fulfill market demands. Ganirelix, a leading peptide active pharmaceutical ingredient (API) primarily used as a gonadotropin-releasing...